



MYOCARDIAL FIBROSIS EVALUATION

Sophie Mavrogeni MD FESC
Onassis Cardiac Surgery Center and Kapodistrian
University of Athens,
Athens Greece



Nothing to disclose



Pathophysiology of myocardial fibrosis

- **Myocardial fibrosis** results from increased **myofibroblast activity** and **excessive extracellular matrix deposition**
- **The detection of myocardial fibrosis relies on:**
 - **Serum markers,**
 - **Cardiac magnetic resonance imaging (CMR)**
 - **Endomyocardial biopsy.**



Types of myocardial fibrosis

- **Replacement fibrosis:** Irreversible collagen deposition following myocyte apoptosis/ necrosis
- **Diffuse myocardial fibrosis:** Reversible, early collagen synthesis/deposition by differentiated myofibroblasts in response to a variety of stimuli.
- **Overlap** of replacement and interstitial fibrosis



CMR in acute/chronic myocardial infarction




Contrast Enhanced MRI (Ce MRI)


- Gadolinium–chelated contrast agents (**Gd**) are the only licensed group of paramagnetic agents for cardiac imaging.
- Gd diffuses rapidly into the interstitial space (strictly **extracellular**), and is eliminated by renal clearance.
- **Scar** appears **bright** compared to normal, dark myocardium.
- **CMR** can visualize as low as **1 gr** scar vs. **10 gr** with **SPECT**.
- **CeMRI** is a robust, well validated and accurate tool to depict myocardial necrosis in both **acute/old MI**.



BRIGHT IS DEAD



TTC




MRI





Ex vivo comparison of TTC and Gd-enhanced MRI in infarcted myocardium



MYOCARDIUM AT RISK




Tissue Characterization of Acute Myocardial Infarction and Myocarditis by CMR






Transmural MI With No-Reflow in a Patient With Reperfused Infarction, Who Presented Late After Onset of Symptoms






Three patients with acute ST-segment–elevation MI treated by primary PCI using the same antithrombotic strategies



- **A**, Patient with no evidence of myocardial hemorrhage or MVO.
- **B**, Patient with T2-hypointense core and MVO, in the absence of hemorrhage.
- **C**, Patient with myocardial hemorrhage




RV myocardial infarction



- Patient with acute inferior and right ventricular (RV) infarction on LGE. (Upper panels)
- Short-axis LEG showing contrast enhancement of the RV. (Middle panels, left).
- Enlarged short-axis view with infarction of the RV wall (black arrowheads) and the inferior left ventricle (white arrows).
- (Middle panels, right) Electrocardiogram with ST-segment elevation in V4r.
- (Lower panels) Culprit right coronary artery lesion in a right dominant perfusion pattern before (left) and after (right) angioplasty. Echocardiography revealed RV hypokinesia and dilatation.




MRI study in a 58 year old male recently diagnosed with dilated cardiomyopathy (LV EF 20%).





ICM in a patient with 3VD





Impact of unrecognized myocardial scar detected by CMR on event-free survival in patients presenting with signs or symptoms of CAD

Myocardial scar detected by cardiac magnetic resonance imaging is the **best predicting factor for patient's survival**, better than ejection fraction and angiographic findings

Kwong RY Circulation 2006; 113(23):2733-43.



Effect of Posterolateral Scar Tissue on Clinical and Improvement After Cardiac Resynchronization Therapy

- CRT does not reduce LV dyssynchrony in patients with **transmural scar tissue in the posterolateral LV segments**, resulting in clinical and echocardiographic nonresponse to CRT.

Bleeker G et al Circulation. 2006;113:969-976



Comparison of ^{18}F SPECT with PET in myocardial imaging: a realistic thorax-cardiac phantom study.

- For smaller defects the $^{99\text{m}}\text{Tc}/^{18}\text{F}$ SPECT imaging cannot entirely replace the more expensive $^{82}\text{Rb}/^{18}\text{F}$ PET for myocardial perfusion/viability imaging, due to poorer image spatial resolution and poorer defect contrast.



Assessment of Myocardial Scar; Comparison Between F-FDG PET, CMR and Tc-Sestamibi.

- There is **considerable variation** amongst these 3 techniques in identifying scarred myocardium in patients with CAD and heart failure.
- More segments were identified as nonviable scar using MIBI than with FDG or CMR.
- We recommend that **MIBI should not be used as the sole imaging modality** in patients undergoing assessment of myocardial viability.



Systematic review and modelling of the cost-effectiveness of CMR compared with current existing testing pathways in ischaemic cardiomyopathy.

- All diagnostic pathways are a cost-effective use of NHS resources.
- The cost-effectiveness analyses suggest that CE CMR and revascularising everyone were the optimal strategies.
- **Future research** should look at:
 - implementation costs for this type of imaging service,
 - provide guidance on reporting of diagnostic testing for viability
 - focus on the impact of revascularisation or best medical therapy



CMR in diffuse myocardial fibrosis



Assessment of interstitial fibrosis

- **T1 mapping:** Measured **without Gd**, reflects the combined **intracellular+extracellular** compartments. Values **increase** with a **greater burden of fibrosis** and are usually measured on a per-segment basis.
- **ECV%** (percentage) and **iECV** (mL or mL/m²) use **Gd to target the extracellular space**.
- **Combination of CMR T1 mapping and LGE** offers a comprehensive assessment of myocardial disease that is **currently unmatched by any other modality**



Clinical significance of T1 mapping



T1 mapping in CAD

- In myocardial infarction T1 mapping can:
- Quantify **infarct size** and
- Differentiate **reversible/irreversible** myocardial injury
- Provide **prognostic importance** of native T1 and ECV in **non-infarcted myocardium**.



T1 mapping in DCM

- **1/3 of DCM demonstrates a non-ischaemic pattern of LGE (mid-wall or subepicardial), which is again a predictor of adverse outcomes (HF, VT)**
- **T1 mapping may discriminate healthy from diseased myocardium, correlating with histology.**
- **T1 mapping is a strong predictor of all-cause mortality and HF, death or hospitalisation, independent of standard measures of risk such as ejection fraction and functional status**



T1 mapping in aortic stenosis (AS)

- The presence of both infarct and non-infarct LGE is independently associated with mortality and once established, **replacement fibrosis progresses rapidly and does not regress** after TAVI.
- Correlations between **diffuse fibrosis** parameters (native T1, ECV% and iECV) and **histology**;



T1 mapping in hypertrophic cardiomyopathy

- Both presence+quantity of **LGE** are independently associated with **all-cause and cardiac death**.
- The **risk of SCD** appears to increase with increasing **LGE burden** a minimum threshold for LGE volume may be of more clinical use.



T1 mapping in myocarditis

- Both native T1 and ECV demonstrate superior correlation with endomyocardial biopsy compared with **Lake Louise criteria** for the diagnosis of acute myocarditis (defined in this study as **≤ 14 days**; area under the curve 0.77, 0.75 and 0.52, respectively).
- **T1 mapping** detects **oedema and reactive fibrosis** in the early inflammatory response.
- However, its value is diminished **if symptoms > 14 days**.



T1 mapping in infiltrative diseases

- **LGE** in a characteristic pattern has a high sensitivity and specificity for **cardiac amyloidosis** as well as **prognostic power for mortality**.
- **ECV%** and **native T1** are **associated with mortality**.
- **LGE** imaging is recommended in the current 2014 Heart Rhythm Society expert consensus criteria to aid in the diagnosis of **cardiac sarcoidosis**.





Cine ED Frame




ShMOLLI T1-map

LGE



Normal
Volunteer



Cardiac
AL amyloid



Aortic
Stenosis





**Greek College of Clinical Applications in CMR
“CARDIOTOMI” and A Cardiac Clinic,
Kapodistrian University of Athens**

ATHENSCMR LEVEL1-2

3-5 October 2020

Coral Hotel

Endorsed by EACVI/SCMR

Accredited by EBAC



“USE CMR TO LEARN PATHOPHYSIOLOGY!”
THANK YOU!

